Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation.

Psoriatic disease is a chronic, systemic immune-mediated inflammatory disorder comprising of three major domains, skin, vascular, and bone/joint inflammation. It is known for a long time that psoriatic disease is associated with a number of conditions such as hypertension, dyslipidemia, diabetes (metabolic syndrome), and depression. Up to one out of five people with psoriasis show concomitant depression. In the past, this was attributed to psychological stress of suffering from a chronic condition that is often visible and itchy, leading to stigmatization and adding to a significant burden of disease. Recent data provide evidence that depression associated with psoriatic disease is linked to the specific inflammatory pattern with IL-23, IL-17 family cytokines, TNF, IL-6, and IL-8 causing neuroinflammation and subsequently depression or depressive behavior and/or anxiety. Psoriatic disease shows a distinct pattern of immune cells (eg. dendritic cells, Th17 cells, neutrophils), mediators (eg. IL-17A/F, IL-23, TNF), and tissue related factors in all major domains of psoriatic disease that is different from other inflammatory dermatoses. There is a striking similarity between the inflammatory pattern in psoriatic disease and neuroinflammation that leads to depression. A number of risk factors have been identified in psoriatic disease, the most important of which are obesity and tobacco smoking. Obesity is known as a major risk factor for depression and anxiety due to its inflammatory signature. Apart from psychotherapy and anti-depressive medication, targeted treatments for psoriasis, including TNF-, IL-17-, and IL-23-inhibitors, can improve depression/depressive symptoms. The review summarizes the current knowledge about depression as a comorbidity in psoriatic disease.